Results

Outcome
One open randomized study compared erythromycin for 7 days with no treatment, 2 and 2 double-blind studies compared amoxicillin/ clavulanic acid (7 or 14 days) with placebo. 3, 4 Mean age ranged from 21 months to 6 years. Antibiotics reduced the proportion of patients not cured at follow-up, with a number needed to treat for an additional beneficial outcome of 3 (95% CI 2 to 4). Antibiotics also decreased illness progression necessitating further therapy, with a number needed to treat for an additional beneficial outcome of 4 (95% CI 3 to 5) (Table) . Adverse events were similar between groups. Authors did not identify significant heterogeneity. They determined 2 studies to be at high or unclear risk of bias and 1 study to be at low risk of bias. Evidence quality was moderate for all outcomes except for antibiotic adverse events (low quality). Subgroup and sensitivity analyses favored patients receiving antibiotics.
Commentary
Approximately 10% of acute presentations to physicians are due to a coughing illness, 5 and prolonged cough in children has an association with greater parental stress. 6 The definition of pediatric prolonged cough is a cough lasting greater than 4 weeks. Classification includes wet (productive) versus dry, and the presence of lower airway secretions defines wet cough. 7, 8 Studies have found protracted bacterial bronchitis to be the most common cause of wet cough in these patients. 9 The definition of protracted bacterial bronchitis is prolonged wet cough without signs or symptoms of an alternative cause that responds to 2 weeks of antibiotic therapy. 9 In pediatric patients with wet cough, one previous systematic review suggested that the majority of patients had lower airway infection with common respiratory bacteria from sputum, thus suggesting a potential benefit of antibiotic therapy. 10 However, the risk of adverse effects may outweigh the benefit of antibiotics in this clinical circumstance.
This meta-analysis sought to evaluate the current evidence in regard to antibiotics in children with prolonged wet cough. It found that antibiotics improved clinical cure rate (number needed to treat for an additional beneficial outcome of 3) and decreased illness progression (number needed to treat for an additional beneficial outcome of 4). Of 3 studies included, 2 examined amoxicillin/clavulanic acid, 3, 4 whereas the third examined erythromycin. 2 Given the bacteriology demonstrated in pediatric patients with wet cough, antibiotics active against these respiratory pathogens may improve clinical cure. These results for pediatric prolonged cough differ from those of previous Cochrane Reviews about antibiotics for the common cold and bronchitis that suggested no benefit to antibiotic therapy. 11, 12 The results of this current meta-analysis should not justify liberal use of antibiotics because the review included only 190 patients from 3 studies (2 with high or unclear risk of bias). Rather, consideration of risks and benefits is necessary, and primary care follow-up for patients who are otherwise well appearing is likely acceptable for these patients.
authors excluded trials comparing 2 or more antibiotics without a placebo arm.
DATA EXTRACTION AND SYNTHESIS
Two authors independently extracted data from included studies. Authors contacted the investigators of included studies for missing data when possible. Primary outcomes included children not cured or substantially improved according to the following hierarchy: objective measurements of cough indices, symptoms as assessed by the child, symptoms as assessed by parents or caregivers, symptoms as assessed by clinicians, airway markers obtained by bronchoalveolar lavage, sputum volume alone, and lung function test results alone. Secondary outcomes included disease progression requiring further medical therapy and antibiotic adverse effects. Authors calculated odds ratios with 95% confidence intervals (CIs) with fixed-effects models and calculated the number needed to treat for an additional beneficial outcome. Authors planned a priori subgroup analyses for children younger than 7 years, control type, variation in duration of treatment, and antibiotic type and planned sensitivity analyses. Investigators assessed heterogeneity with the I 2 and c 2 tests, and 2 authors independently assessed risk of bias based on the Cochrane Handbook for Systematic Reviews of Interventions, with disagreements resolved by either consensus or discussion with a third author. 1 The inclusion of patients with cough for greater than 10 days is a limitation because it implies that study results apply to a potentially heterogeneous patient population with wide variation in terms of duration of symptoms. This heterogeneity may be problematic insofar as patients with longer duration of symptoms may be more likely to benefit from antibiotics. Indeed, many included patients had cough duration exceeding 3 weeks. [2] [3] [4] The randomization used in each of the included studies makes it likely that spontaneous resolution occurred equally in treatment and placebo groups. Nevertheless, the study findings may be less generalizable to patients with relatively shorter duration of symptoms (eg, 11 days). Other limitations of this meta-analysis include different antibiotics and dosages used. Studies used different treatment durations, and authors were unable to compare short-and longterm duration therapy. None of the included studies used longterm follow-up, and recurrence rates are not known. One included study specifically excluded patients with allergy, 2 which is important because allergic rhinitis and ongoing seasonal allergies are often implicated in prolonged cough. Results are limited to patients who otherwise appeared well and did not have other signs of underlying lung conditions. Finally, although authors found similar rates of adverse events in patients receiving antibiotics, this evidence was of low quality.
According to this meta-analysis, antibiotics may improve clinical cure and reduce progression of illness in children with prolonged wet cough who are otherwise well appearing and with no other known pulmonary conditions. 13 Further data are necessary to evaluate the specific duration of therapy with validated objective measures of outcome, subgroups such as individuals with allergic rhinitis and ongoing seasonal allergies, and the use of amoxicillin/clavulanic acid. More data about adverse effects of antibiotics in this patient population are also necessary.
